Calendario de promoción Indaptus Therapeutics, Inc.
Horario avanzado
gráfico sencillo
Acerca de la empresa
Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as chronic hepatitis B virus and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. Más detalles| EBITDA | -0.0341 |
|---|---|
| EV/EBITDA | -0.2592 |
| IPO date | 2015-08-04 |
| ISIN | US45339J1051 |
| Industry | Biotechnology |
| P/BV | 1.46 |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Сайт | https://indaptusrx.com |
| Цена ао | 2.8 |
| Число акций ао | 0.0084 млрд |
| Cambio de precio por día: | -0.8475% (1.18) |
|---|---|
| Cambio de precio por semana.: | +10.38% (1.06) |
| Cambio de precio por mes: | -19.31% (1.45) |
| Cambio de precio en 3 meses.: | -47.06% (2.21) |
| Cambio de precio en seis meses: | -50.94% (2.385) |
| Cambio de precio por año: | -55.34% (2.62) |
| Cambio de precio en 3 años.: | -87.65% (9.47) |
| Cambio de precio en 5 años.: | +62.55% (0.7198) |
| Cambio de precio desde principios de año.: | -53.01% (2.49) |
|
|
Subestimación
|
Eficiencia
|
|||||||||||||||||||||||||||||||||||||
Dividendos
|
Deber
|
Impulso de crecimiento
|
|||||||||||||||||||||||||||||||||||||
| Instituciones | Volumen | Compartir, % |
|---|---|---|
| Vanguard Group Inc | 256265 | 3 |
| Investment House, LLC | 102437 | 1.2 |
| Geode Capital Management, LLC | 54767 | 0.64 |
| Strategy Asset Managers Llc | 45336 | 0.53 |
| Pine Valley Investments Ltd Liability Co | 44240 | 0.52 |
| Renaissance Technologies, LLC | 29400 | 0.34 |
| Vivaldi Capital Management Lp | 24000 | 0.28 |
| State Street Corporation | 19473 | 0.23 |
| Citadel Advisors Llc | 16518 | 0.19 |
| Tower Research Capital LLC (TRC) | 4696 | 0.05 |
| Supervisor | Título profesional | Pago | año de nacimiento |
|---|---|---|---|
| Mr. Jeffrey A. Meckler | CEO & Director | 867.03k | 1967 (57 años) |
| Mr. Walt Addison Linscott Esq. | Chief Operating Officer | 716.35k | 1961 (63 año) |
| Dr. Michael J. Newman Ph.D. | Founder, Chief Scientific Officer & Director | 659.99k | 1956 (68 años) |
| Mr. Nir Sassi | CFO, Secretary & Treasurer | 378.47k | 1976 (48 años) |
| Dr. Roger J. Waltzman M.B.A., M.D. | Chief Medical Officer | N/A | 1968 (56 años) |
DIRECCIÓN: United States, New York. NY, Three Columbus Circle - abrir en mapas de google, abrir mapas de Yandex
Sitio web: https://indaptusrx.com
Sitio web: https://indaptusrx.com
